Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
A phase 3 trial of Puxitatug samrotecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by AstraZeneca, now recruiting.
Overview
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) is a phase 3 interventional study registered as NCT07044336 by AstraZeneca, with 800 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-10-15. Interventions recorded: Puxitatug Samrotecan, Doxorubicin, Paclitaxel. Conditions listed: Endometrial Cancer, Malignant Solid Tumour. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Shares Puxitatug samrotecan, Endometrial cancer, AstraZeneca.
- TrialA Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialStudy of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Shares Doxorubicin, Endometrial cancer.
- TrialA Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment
Shares Endometrial cancer, AstraZeneca.
- TrialDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC
Shares Paclitaxel / nab-paclitaxel, Endometrial cancer, AstraZeneca.